CTTI is pleased to welcome its newest members, Alnylam Pharmaceuticals and the American Society of Clinical Oncology (ASCO).

Alnylam Pharmaceuticals is a pharmaceutical company focusing on the development of new therapeutics that use the RNA interference process to silence disease-causing genes. Their representative joining CTTI’s Steering Committee is Pushkal Garg, Senior Vice President, Clinical Development.

ASCO is the leading professional organization for physicians and oncology professionals caring for people with cancer. Their representative joining CTTI’s Steering Committee is Patricia Hurley, Associate Director, Research and Analysis, Policy and Advocacy Department.

Alnylam and ASCO join over 80 other diverse member organizations that are collaborating with CTTI to develop solutions with real-world impact. CTTI actively engages all stakeholders equally to improve the quality and efficiency of the clinical trials enterprise. Learn more about our diverse membership.

*These numbers reflect organizations on CTTI’s Steering Committee. In addition, our membership includes 3 individual patient/caregiver representatives.